Introduction
============

Resistance to therapy is a primary cause of treatment failure in most human cancers [@B1], [@B2]. Pancreatic cancer (PC), one of the most challenging malignancies to treat, is characterized by aggressive local invasion, early metastasis, and a high degree of resistance to therapy. Patients with this lethal malignancy have an average 5-year survival rate of only 4% [@B3]. At present, surgical resection offers the only potential cure; however, 80%-85% of PC patients are diagnosed with advanced disease, which usually precludes complete resection [@B3]. Cytotoxic therapy is routinely used to treat both resectable and unresectable PC cases; however, only a small subset of patients responds to treatment, resulting in limited overall benefit, and despite intense research there has been little progress in the development of more effective therapies. Gemcitabine (GEM) and GEM-based chemotherapeutic combinations are standard treatments for PC, but exhibit a low response rate (24%) and a poor increase in median overall survival time (5.7 months) [@B4], [@B5]. FOLFIRINOX was recently adopted as a treatment option for patients with advanced PC, but it exhibits increased toxicity for a modest improvement in median overall survival time (11 months) [@B6]. Drug resistance is thought to be a major reason for treatment failure, indicating an urgent need to identify and apply predictive markers to segregate PC patients into personalized treatment regimens to minimize therapy resistance.

Molecular and genomic research of PC suggests that varying responses to therapy may be attributable to tumor heterogeneity, implying that metastases may exhibit divergent responses due to clonal diversity [@B7]. Recent studies also indicate that cell-cell communications in the tumor microenvironment may be involved in therapy resistance [@B1], [@B8]. Tumor-derived exosomes contain proteins and nucleic acids that can serve as key mediators in cell-cell communications, increasing tumor progression and metastasis [@B9]-[@B15]. We hypothesized that exosomal transfer of a resistance factor from a chemoresistant PC tumors might also be able to increase chemoresistance of more susceptible PC clones. We therefore analyzed exosomes secreted by PC cell lines with variable GEM sensitivity to identify exosomal proteins that could transfer GEM resistance between PC cell lines. Our results indicate that Ephrin type-A receptor 2 (EphA2) expression was required for exosome-mediated transfer of GEM-resistance.

Results
=======

Exosomes derived from chemoresistant PC cells confer GEM resistance
-------------------------------------------------------------------

Studying mechanisms of tumor chemoresistance *in vivo* is challenging due to the heterogeneous nature of the tumor microenvironment. We therefore utilized *in vitro* cell culture to characterize the ability of PC-derived exosomes to increase resistance to GEM, a standard component of most PC treatment regimens, in a proof-of-concept study. We found that three well-characterized PC cell lines (PANC-1, MIA PaCa-2, and BxPC-3) displayed differential resistance to GEM, in agreement with previous observations [@B16]-[@B19], with PANC-1 cells exhibiting significantly greater GEM resistance than MIA PaCa-2 and BxPC-3 cells (Figure [S1](#SM0){ref-type="supplementary-material"}).

Exosomes were isolated from PANC-1 (GEM-resistant) and MIA PaCa-2 and BxPC-3 (GEM-sensitive) cell cultures by ultracentrifugation [@B20]. Transmission electron microscopy (TEM) analyses revealed characteristic cup-shaped exosomal morphology (Figure [1](#F1){ref-type="fig"}A and Figure [S2](#SM0){ref-type="supplementary-material"}) and dynamic light scattering studies found a typical size range of 30-100nm (Figure [S3](#SM0){ref-type="supplementary-material"}) [@B21], indicating that isolated vesicles were enriched in exosomes but not larger extracellular microvesicles. Western blot analyses detected the exosome markers CD63, CD9, and TSG101, while the Golgi protein marker GM130 was undetectable (Figure [1](#F1){ref-type="fig"}B), confirming the purity of these exosome preparations.

To determine if exosomes derived from GEM-resistant PC cells conferred resistance to GEM-sensitive PC cells, chemo-sensitive MIA PaCa-2 or BxPC-3 cultures were incubated with PANC-1 exosomes for 24 h (Figure [1](#F1){ref-type="fig"}C) and then challenged with GEM for 3 days, with fresh exosomes added every 24 h. PANC-1 exosome treatment significantly increased the GEM-resistance of MIA PaCa-2 and BxPC-3 cells (Figure [1](#F1){ref-type="fig"}D-E) corresponding to the exosome dose (Figure [S4](#SM0){ref-type="supplementary-material"}A-B). Further, fluorescent labeling revealed that PANC-1 exosomes were internalized by recipient cells (Figure [1](#F1){ref-type="fig"}F), suggesting that chemoresistance was mediated by delivery of exosome factors to the cell membrane and/or cytoplasm. In contrast, no change in viability was observed when MIA PaCa-2 cells were co-cultured with BxPC-3 exosomes or *vice versa* (Figure [1](#F1){ref-type="fig"}D-E and Figure [S4](#SM0){ref-type="supplementary-material"}C-D), demonstrating that exosomes of GEM-sensitive cells did not confer chemoresistance.

Identification of exosomal proteins associated with transfer of GEM resistance
------------------------------------------------------------------------------

Exosomes of each cell line were extracted for protein, which was size-fractionated by SDS-PAGE and silver-stained to detect candidate chemoresistance proteins overexpressed in PANC-1 vs. MIA PaCa-2 and BxPC-3 exosomes (Figure [2](#F2){ref-type="fig"}A-B). LC-MS/MS data from bands 1 and 2 used to query the UniProtKB/Swiss-Prot *Homo sapiens* databases identified 15 proteins, each with at least one unique peptide, that were differentially expressed with scores of \>30 (Table [1](#T1){ref-type="table"}). We selected the two highest scoring proteins, EphA2 and Erythrocyte band 7 integral membrane protein (stomatin), which were derived from band 1 and 2, respectively. EphA2 expression was \~5-fold higher in PANC-1 *vs.* MIA PaCa-2 and BxPC-3 exosomes, while stomatin expression was not differentially overexpressed in PANC-1 exosomes, leading us to focus on EphA2 (Figure [2](#F2){ref-type="fig"}C-D).

Exosomal EphA2 mediates transmission of GEM resistance to GEM-sensitive PC cells
--------------------------------------------------------------------------------

To determine whether exosomal EphA2 (EXO_EphA2) was responsible for transmission of GEM resistance to GEM-sensitive cells, we generated PANC-1 cultures where \>90% of cells stably expressed EphA2 shRNA (Figure [S5](#SM0){ref-type="supplementary-material"}). PANC-1 cells expressing EphA2-shRNA-1 (PANC-1^EphA2-^) revealed a \~80% decrease in EphA2 expression and a \~25% decrease in resistance to 100 nM GEM (Figure [3](#F3){ref-type="fig"}A-C), and their exosomes failed to transfer chemoresistance to GEM-sensitive MIA PaCa-2 and BxPC-3 cells (Figure [3](#F3){ref-type="fig"}D-E). To address whether exosomal delivery is required for the EphA2-mediated chemoresistance effect, MIA PaCa-2 and BxPC-3 cells were incubated with bioactive recombinant EphA2, both before and during GEM treatment. MIA PaCa-2 or BxPC-3 cells treated with recombinant EphA2 protein did not exhibit altered responses to GEM, and failed to demonstrate EphA2 protein uptake (Figure [S6](#SM0){ref-type="supplementary-material"}), unlike THP-1 macrophages that exhibited marked accumulation of free EphA2 during this incubation period. These results strongly suggest that exosome protein delivery played a critical role in EphA2-mediated GEM resistance.

Exosome uptake by chemosensitive PC cells is independent of EXO_EphA2 expression
--------------------------------------------------------------------------------

Exosome fusion with a plasma membrane transfers soluble and membrane-associated factors to recipient cells and blocking this uptake can inhibit exosome-mediated phenotypes. EXO-Red-labeled PANC-1^EphA2-^ and PANC-1^Ctrl_shRNA^ exosomes were both efficiently internalized by MIA PaCa-2 and BxPC-3 cells (Figure [4](#F4){ref-type="fig"}A), which revealed similar uptake of exosomes derived from PANC-1, PANC-1^EphA2-^ or PANC-1^Ctrl_shRNA^ cells (Figure [4](#F4){ref-type="fig"}B-C), indicating that exosome uptake was independent of EXO_EphA2 expression.

EphA2 expression in MIA PaCa-2 and BxPC-3 cells increased dose-dependently after incubation with PANC-1 exosomes (Figure [5](#F5){ref-type="fig"}A-B) revealing a 1.5-fold increase at the highest dose, while PANC1^EphA2-^ exosomes failed to increase cellular EphA2 expression, even after incubation with a 20 µg/mL exosome dose (Figure [5](#F5){ref-type="fig"}C-D).

Discussion
==========

Resistance to therapy contributes to poor PC patient outcomes [@B22], [@B23]. Exosomes present in tumor microenvironments can be internalized by adjacent cells and modify the phenotype of the recipient cell to reflect the regulatory functions of the exosome cargo. Our study results now indicate that PC tumor exosomes can transmit chemoresistance, potentially allowing chemoresistant PC cells to transfer resistance to sensitive PC cells within the same tumor or at other anatomical sites. Chemoresistance transfer from GEM-resistant to GEM-sensitive PC cells was found to correspond with and require EXO_EphA2 expression.

Multiple proteomic and metabolomic studies have attempted to define the intracellular circuitry governing PC chemoresistance [@B24]-[@B29], but few have focused on the role of PC-derived exosomes, which our results now indicate can transfer GEM-resistance *via* an EphA2-dependent mechanism. Most previous reports have focused on exosome-mediated affects to promote rather than transfer resistance to chemotoxic agents or radiation exposure, and tend to identify relatively non-specific mechanisms. For example, one study has proposed that exosomes can function as drug exporters to promote chemoresistance, finding that doxorubicin accumulates in shed vesicles and that chemoresistance corresponds with vesicle shedding rate across a variety of cell lines [@B30]. Exosome transfer from stromal cells to breast cancer cells has also been reported to promote STAT-1-dependent radiation resistance by exosomal RNA-mediated activation of the RIG-I pattern recognition receptor [@B13]. Few studies have examined the ability of exosomes of chemoresistant cancer cells to transfer drug resistance. One study has proposed that exosome-mediated miRNA transfer from docetaxel-resistant to docetaxel-sensitive breast cancer cells may enhance drug resistance through an affect to decrease expression of the tumor suppressor protein PTEN [@B31]. We believe our results, however, provide the first example of direct exosomal transfer of a chemoresistance factor altering the chemoresistance phenotype of the recipient cell.

EphA2 is overexpressed and mediates therapy resistance in breast cancer, cervical cancer, and melanoma [@B32]-[@B36]. Recent studies have revealed that EphA2 repression attenuates PC invasiveness and increases melanoma sensitivity to vemurafenib and breast cancer sensitivity to tamoxifen [@B36]-[@B38], suggesting that EphA2 represents a promising target for future cancer therapeutics. Our results reveal a previously unknown ability of EphA2-enriched exosomes to transfer chemoresistance. Improving the predictability of a patient\'s response to therapy is urgently required to customize therapy and improve overall survival, particularly for PC patients, who have poor therapy response rates that lead to rapid patient mortality. Despite great effort expended on biomarker development, effective predictive markers for PC treatment remain elusive [@B39]. Characterization of exosomal factors that regulate chemoresistance may serve as a robust source of functional biomarkers. Our findings suggest that EXO_EphA2 may play an important role in PC drug resistance, and implies that it may be useful to analyze other specific exosome sub-populations as biomarkers of PC drug resistance. Future studies need to be performed in PC patient populations with well-defined treatment regimens to validate the clinical utility of EXO_EphA2, and other potential exosome factors, as a biomarker of PC drug resistance. Validation of EXO_EphA2 level as a biomarker of PC drug resistance would allow affected patients to be assigned to EphA2-targeted therapeutic regimens, several which are currently under study, to offer a targeted approach to individual therapy.

Materials and Methods
=====================

Materials
---------

The PC cell lines PANC-1, MIA PaCa-2, and BxPC-3 were purchased from the American Type Culture Collection (Manassas, VA). Bovine growth serum, RPMI 1640, and DMEM medium were purchased from HyClone (Logan, UT). GEM was purchased from the pharmacy at Houston Methodist Research Institute and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was obtained from Life Technologies (Grand Island, NY). Puromycin was purchased from Invitrogen (Carlsbad, CA). Mouse monoclonal anti-CD9, rabbit polyclonal anti-CD63, goat polyclonal anti-Stomatin, and mouse monoclonal anti-GAPDH antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Mouse monoclonal anti-TSG101 and rabbit monoclonal anti-GM130 antibodies were purchased from Abcam (Cambridge, MA). Mouse monoclonal anti-EphA2 antibody was purchased from Millipore (Billerica, MA). GIPZ Lentiviral EphA2 shRNAs were purchased from GE Dharmacon (Lafayette, CO).

Cell culture
------------

PANC-1 and BxPC-3 cells were cultured in RPMI 1640 containing 10% fetal bovine serum (FBS), and MIA PaCa-2 cells in DMEM with 10% FBS for growth or maintenance or serum-free medium for exosome collection. Cultures were incubated at 37°C in a humidified 5% CO~2~ incubator and supplemented with penicillin (100 U) and streptomycin (100µg/mL).

Exosome isolation and analyses
------------------------------

Exosomes were isolated using a slight modification of an established protocol [@B20], [@B40], [@B41]. Briefly, cells were cultured with 10% FBS until reaching 70% confluence, washed 3x with PBS, then cultured for 48h in serum-free medium, after which supernatants were collected and centrifuged for 10 min at 300×*g* at 4°C to remove dead cells, then transferred and centrifuged for 30 min at 9000×*g* to remove cell debris. Supernatant was centrifuged at 100,000×*g* for 2 h to generate exosome pellets, which were resuspended in PBS and then centrifuged at 100,000×g for 2 h at 4°C, and resulting exosome pellets were resuspended in PBS for characterization or use in cell culture experiments or dissolved in M-PER mammalian protein extraction reagent (Pierce, Rockford, IL) for Western blot analyses.

Dynamic light scattering was performed with 10 µg of PBS-resuspended exosomes to generate size distribution data that was analyzed using Zetasizer Software. For TEM analyses, 10 µL of purified exosome fraction (100 µg/mL) was placed on non-glow-discharged carbon-coated grids for 10 min and then negatively stained with 10 µL of 2% uranyl acetate for 1 min, after which negative stain solution was removed by wicking onto filter paper, and the dried grids were viewed using a Philips/FEI CM-12 transmission electron microscope operated at 80 KeV [@B20].

Determination of protein concentration
--------------------------------------

Whole cells or purified exosomes were lysed in M-PER mammalian protein extraction reagent in the presence of a protease inhibitor cocktail (Pierce, Rockford, IL). The protein concentration was determined using a bicinchoninic acid (BCA) assay kit (Pierce, Rockford, IL) according to the manufacturer\'s instructions.

Western blot analysis
---------------------

Western blot assays were performed with precast Tris-Bis 4%-15% gradient gels and nitrocellulose membranes (Bio-Rad, Richmond, CA) using standard methods. Specific protein signals in loaded whole-cell lysates (WCLs, 20 µg) or exosome lysates (EXOs, 10 µg) were analyzed by densitometric analyses normalized to a loading control or an internal standard.

Isolation and identification of exosomal proteins
-------------------------------------------------

Exosomal proteins were isolated and identified using a previously described method [@B42], [@B43]. Briefly, silver-stained SDS-PAGE gel slices were digested with trypsin, and the digests were separated using Ultimate 3000 nano-LC (Dionex Corporation, USA) with a nC18 enrichment column (Dionex C18 Pepmap 100, 5 µm particle, 100 Å pore, 300 µm i.d. ×5 mm) and a Dionex nC18 analytical column (C18 Pepmap 100, 3 µm particle, 100 Å pore, 75 µm i.d. ×150 mm). Each 10 µL sample was dried by vacuum centrifugation and resuspended to \~20 µL with 0.1% formic acid/2% acetonitrile before injection. Flow rates of 20 µL/min and 300 nL/min were used for the loading and analytical columns, respectively. Eluted peptides were analyzed on a linear ion trap LTQ Velos Pro mass spectrometer (Thermo Scientific, San Jose, CA). One MS scan was followed by eight MS/MS scans, and MS/MS spectra were queried against the UniProt database ([www.uniprot.org](http://www.uniprot.org)) using in-house Mascot 2.3.0 ([www.matrixscience.com](http://www.matrixscience.com)) software and a mass tolerance of 0.5 Da.

EphA2 shRNA knockdown
---------------------

PANC-1 cells were transduced with lentiviral vectors expressing Eph2A (EphA2_shRNA_1: 5\'-GAACTTCAACACAGCCTGG-3\' or EphA2_shRNA_2: 5\'-AGAGGTTGAAAGTCTCCTT-3\') or control (Ctrl_shRNA) shRNA, then incubated with 10 µg/mL puromycin (Invitrogen, Carlsbad, CA) for 2 days to select for transduced cells, with EphA2 expression knockdown confirmed by Western blot.

GEM sensitivity assays
----------------------

Cells were seeded in 96-well plates at a density of 2×10^3^ cells/well (MIA PaCa-2 cells) or 3×10^3^ cells/well (PANC-1 and BxPC-3 cells) and allowed to attach for 24 h, then cultured for 72 h with 1-100 nM GEM, as indicated. MTT (5 mg/mL) was then added to each well, and after 4 h the media was aspirated and 100 µL of DMSO was added to dissolve formazan crystals. Plates were gently agitated for 5 min and absorbance was measured at 570 nm and 630 nm to determine cell viability.

For EphA2-mediated viability studies, MIA PaCa-2 and BxPC-3 cells were seeded in 24-well plates (1×10^5^ cells/well), cultured for 24 h in serum-containing media supplemented with 0, 5, 10, or 20 µg/mL PANC-1 or PANC-1^EphA2-^ exosomes, or 0.04, 0.2 or 0.5µg/mL recombinant EphA2, then re-seeded into 96-well plates (2 × 10^3^ cells/well MIA PaCa-2; 3 × 10^3^ cells/well BxPC-3) and cultured for 3 days with 0, 25, 50, or 100 nM GEM, with fresh exosomes added every 24 h, and then analyzed by MTT cell viability assays according to the manufacturer\'s instructions.

Exosome internalization
-----------------------

Exosomes were labeled with EXO-Red (System Biosciences, Mountain View, CA) according to the manufacturer\'s recommendations. MIA PaCa-2, BxPC-3 cells and THP-1 cells were plated at 2.5×10^4^ cells/well in 8 well chamber slides (BD Falcon, Bedford, MA), allowed to adhere for 24 h in serum-containing medium, washed 3x with PBS, cultured for 2 h at 37°C in serum-containing medium supplemented with 20 µg/mL EXO-Red-labeled PANC-1 exosomes or 0.5 µg/mL recombinant fluorescent-labeled EphA2 protein. THP-1 monocytes were treated with 50 ng/mL phorbol 12-myristate 13-acetate (PMA) to differentiate into macrophage. Recombinant EphA2 was labeled with Alexa Fluor 488 dyes according to the manufacturer\'s instructions. For microscopy studies, cells were washed 3x with PBS, incubated for 15 min at 25°C with 4% paraformaldehyde, and incubated for 5 min at 25°C in 1:1000 4\'6-diamidino-2-phenylindole (DAPI)/PBS solution, and exosomes were visualized using a laser scanning confocal microscope with a 40× objective (FV-100; Olympus). For flow cytometry studies, cells were PBS washed, detached, PBS washed, diluted in PBS with 10% BSA, and then analyzed on a BD FACS AriaII (BD Biosciences, San Jose, CA) to measure exosome uptake by florescence intensity [@B44].

Statistical analysis
--------------------

Statistical analysis was performed using one-way or two-way ANOVA with post hoc Bonferroni tests for each individual comparison. GraphPad Prism software (San Diego, CA) was used to perform the calculations. Differences with a *p-*value \<0.05 were considered statistically significant. Data were expressed as the mean±SD (n≥3).
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![**Exosomes of GEM-resistant PC cells can transfer chemoresistance.** (**A**) TEM image of exosomes isolated from PANC-1 cells and negatively stained by uranyl acetate (arrows). (**B**) Western blot analysis of exosomes (EXOs) and whole-cell lysates (WCLs) of PANC-1, MIA PaCa-2, and BxPC-3 cells for exosome (CD63, CD9, and TSG101) and golgi (GM130) protein markers. (**C**) Experimental design of exosome uptake studies. (**D-E**) GEM cytotoxicity in (**D**) MIA PaCa-2 cells or (**E**) BxPC-3 after 24 h pre-treatment with 20 µg/mL exosomes from PANC-1 (EXO_PANC-1), BxPC-3 (EXO_BxPC-3) or MIA PaCa-2 (EXO_MIA PaCa-2) cells, with fresh exosomes added every 24 h of the 3 day GEM treatment. Cell viability is presented as a percentage of control (no drug or exosomes) viability. (**F**) Exosome internalization in MIA PaCa-2 and BxPC-3 cells incubated for 2 h with or without EXO-Red-stained exosomes and then stained with DAPI for nuclear visualization. Bar indicates 10 µm; Data indicate mean±SD; n=6; \**p*\<0.05; \*\**p*\<0.01, \*\*\**p*\<0.001.](thnov08p5986g001){#F1}

![**Identification of candidate exosome chemoresistance proteins.** (**A**) Western blot of exosomal proteins of MIA PaCa-2, PANC-1, and BxPC-3 cells (arrows indicate protein bands subjected to LC-MS/MS sequence analysis). (**B**) Relative expression of selected exosomal protein bands normalized to the sum of the band densities in each lane. (**C**) Western blot of candidate proteins in WCLs and EXOs of PANC-1, MIA PaCa-2, and BxPC-3 cells. (**D**) Relative exosome EphA2 and Stomatin expression. Data indicate mean±SD (n=3); \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001.](thnov08p5986g002){#F2}

![**Exosomal EphA2 confers GEM resistance.** (**A**) Western blot and (**B**) GAPDH-normalized EphA2 levels in PANC-1 cells transduced with lentiviruses expressing EphA2_shRNA_1, EphA2_shRNA_2, or Ctrl_shRNA. (**C**) Viability of PANC-1^Ctrl_shRNA^ and PANC-1^EphA2-^ (EphA2_shRNA_1 transduced) cells after 72h GEM treatment, normalized to untreated cell viability. (**D-E**) GEM cytotoxicity (100nM for 72 h) in (**D**) MIA PaCa-2 and (**E**) BxPC-3 cells after exposure to 20 µg/mL EXO_PANC-1 or EXO_PANC-1^EphaA2-^ or recombinant EphA2 (0.5 µg/mL). Data represent mean±SD; Western: n=3; MTT assay: n=6; \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001.](thnov08p5986g003){#F3}

![**Exosomal EphA2 expression does not affect exosome internalization.** (**A**) Confocal images of MIA PaCa-2 and BxPC-3 cells mock-treated or incubated for 2 h with the indicated EXO-Red-stained exosomes, then fixed, permeabilized, and stained with DAPI (blue). The scale bar represents 10 µm. (**B**-**C**) Flow cytometric analysis of the fluorescence intensity of (**B**) BxPC-3 and (**C**) MIA PaCa-2 cells after 2h co-culture with the indicated EXO-Red-labeled exosomes.](thnov08p5986g004){#F4}

![**EphA2 uptake by recipient PC cells.** (**A and C**) Western blots of MIA PaCa-2 and BxPC3 WCLs after 96 h culture with (**A**) PANC-1 or (**C**) PANC-1^EphA2-^ exosomes. (**B and D**) GAPDH-normalized EphA2 expression. Data represent mean±SD; n=3; \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001.](thnov08p5986g005){#F5}

###### 

Proteins identified by LC MS/MS sequence from exosomal bands 1 and 2.

  No.   Protein name                                   ID       Score   No. of peptides   Band
  ----- ---------------------------------------------- -------- ------- ----------------- ------
  1     Ephrin type-A receptor 2                       P29317   124     6                 1
  2     Erythrocyte band 7 integral membrane protein   P27105   115     2                 2
  3     MARCKS-related protein                         P49006   90      4                 1
  4     Protein eva-1 homolog B                        P58658   88      2                 2
  5     14-3-3 protein eta                             Q04917   79      4                 2
  6     Lactadherin                                    Q08431   70      4                 1
  7     14-3-3 protein sigma                           P31947   53      2                 2
  8     CD44 antigen                                   P16070   45      1                 2
  9     Cytochrome b-c1 complex subunit 2              P22695   43      1                 1
  10    Inter-alpha-trypsin inhibitor heavy chain H2   P19823   43      1                 1
  11    Ribonuclease inhibitor                         P13489   40      1                 1
  12    Retinoic acid-induced protein 3                Q8NFJ5   40      1                 1
  13    Rho GDP-dissociation inhibitor 1               P52565   38      1                 2
  14    Integrin alpha-6                               P23229   38      1                 2
  15    Perilipin-3                                    O60664   38      1                 2
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